EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Medical Management of Hypertrophic Cardiomyopathy

Mohit D Gupta, Vrinda Goel, M P Girish

Indian Heart Journal · 2026-09 · 78 (5) · 267-276

DOI: 10.1016/j.ihj.2026.06.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Indian Heart Journal, 2026-09. Verfasst von Mohit D Gupta und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, GB Pant Institute of Postgraduate Medical, Education and Research, New Delhi, India. Electronic address: drmohitgupta@yahoo…. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Disease Management, Adrenergic beta-Antagonists, Calcium Channel Blockers. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertrophic cardiomyopathy (HCM) is a genetically determined myocardial disease in which symptoms are driven not simply by ventricular hypertrophy, but by a combination of dynamic left ventricular outflow tract obstruction (LVOTO), impaired diastolic filling and other factors.The therapy for HCM differs fundamentally from routine heart failure management and must be mechanism based. In obstructive HCM, the pharmacologic objective is to blunt hypercontractility, lengthen diastole, preserve loading conditions, and reduce the LVOT gradient. In non-obstructive HCM, management is focused on symptom control, heart-rate moderation, careful volume management, and treatment of arrhythmias and congestion. Non-vasodilating beta-blockers, non-dihydropyridine calcium-channel blockers, and disopyramide have constituted the foundation of medical therapy. The contemporary era has added sarcomere-directed treatment with cardiac myosin inhibitors, particularly mavacamten and aficamten, The present review provides a pragmatic algorithm for publication-level clinical use in contemporary practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicDisease ManagementAdrenergic beta-AntagonistsCalcium Channel BlockersHumansAnti-Arrhythmia Agents

Stichwörter der Autor:innen

AficamtenAtrial fibrillationBeta-blockerDisopyramideHypertrophic cardiomyopathyLVOT obstructionMavacamtenMedical management

Substanzen

Adrenergic beta-AntagonistsAnti-Arrhythmia AgentsCalcium Channel Blockers

Autor:innen und Institutionen

  • Department of Cardiology, GB Pant Institute of Postgraduate Medical, Education and Research, New Delhi, India. Electronic address: drmohitgupta@yahoo.com.
  • Department of Cardiology, GB Pant Institute of Postgraduate Medical, Education and Research, New Delhi, India.

Zitieren

APA

Gupta, M. D., Goel, V., & Girish, M. P. (2026). Medical Management of Hypertrophic Cardiomyopathy. Indian Heart Journal, 78(5), 267-276. https://doi.org/10.1016/j.ihj.2026.06.005

Vancouver

Gupta MD, Goel V, Girish MP. Medical Management of Hypertrophic Cardiomyopathy. Indian Heart Journal. 2026;78(5):267-276. doi:10.1016/j.ihj.2026.06.005

BibTeX
@article{Gupta2026,
  author = {Gupta, Mohit D and Goel, Vrinda and Girish, M P},
  title = {Medical Management of Hypertrophic Cardiomyopathy},
  journal = {Indian Heart Journal},
  year = {2026},
  volume = {78},
  number = {5},
  pages = {267--276},
  doi = {10.1016/j.ihj.2026.06.005}
}
Kostenlos starten →